Pharmanutra S.p.A.
PHN.MI · MIL
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 1.05 | -2.88 | 4.06 | -25.62 |
| FCF Yield | 3.11% | -0.21% | -1.44% | 2.11% |
| EV / EBITDA | 16.60 | 20.90 | 24.31 | 35.64 |
| Quality | ||||
| ROIC | 17.58% | 14.42% | 18.99% | 24.69% |
| Gross Margin | 71.28% | 48.45% | 36.17% | 47.18% |
| Cash Conversion Ratio | 1.24 | 0.94 | 0.96 | 1.48 |
| Growth | ||||
| Revenue 3-Year CAGR | 11.68% | 14.03% | 12.56% | 8.19% |
| Free Cash Flow Growth | 1,504.49% | 86.69% | -156.34% | 47.45% |
| Safety | ||||
| Net Debt / EBITDA | 0.27 | 0.34 | -0.18 | -1.16 |
| Interest Coverage | 15.94 | 19.58 | 69.19 | 78.21 |
| Efficiency | ||||
| Inventory Turnover | 8.20 | 6.38 | 10.12 | 15.09 |
| Cash Conversion Cycle | 15.21 | 46.22 | 15.03 | 47.13 |